Phase II Study of the Dose Adjusted EPOCH Regimen in Combination With Ofatumumab/Rituximab as Therapy for Patients With Newly Diagnosed or Relapsed/Refractory Burkitt Leukemia or Relapsed/Refractory Acute Lymphoblastic Leukemia

Trial Profile

Phase II Study of the Dose Adjusted EPOCH Regimen in Combination With Ofatumumab/Rituximab as Therapy for Patients With Newly Diagnosed or Relapsed/Refractory Burkitt Leukemia or Relapsed/Refractory Acute Lymphoblastic Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Ofatumumab (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Pegfilgrastim; Prednisone; Vincristine
  • Indications Acute lymphoblastic leukaemia; Burkitt's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Oct 2016 Indication 'Acute lymphoblastic leukemia' was added.
    • 14 Jan 2015 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2019, according to ClinicalTrials.gov record.
    • 14 Jan 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top